Neola Medical EN
  • Lung Monitoring
  • The Technology
  • Our Studies
  • About Us
  • Career
  • Investors
    • To invest in Neola Medical
    • Risks and uncertainties
    • Stock information
    • Annual General Meeting (Swedish)
    • Corporate governance
    • Certified Adviser
    • Rights Issues (Swedish)
      • Riktad Emission 2023
      • Företrädesemission 2022
      • IPO 2020
        • Teckningsoptioner av serie TO1
    • Investor Relations
    • Investor letters
    • Presentations
    • Press Releases
    • Reports and Financial Calendar
  • News
    • Press Releases
    • Articles and posts
      • 2018 – 2024
      • 2025
Select Page
Neola Medical’s new trademark has been registered in the European Union

Neola Medical’s new trademark has been registered in the European Union

Oct 13, 2022

This is a translation of the Swedish press release published 2022-10-13 Neola Medical AB (publ) announces today that the company’s new trademark has been registered in the European Union. The new trademark is part of the company’s name change that was implemented the...
New scientific article in Pediatric Research shows the benefits of the technology used by Neola Medical for continuous lung monitoring

New scientific article in Pediatric Research shows the benefits of the technology used by Neola Medical for continuous lung monitoring

Oct 5, 2022

This is a translation of the Swedish press release published 2022-10-05 A new scientific article has been published in Pediatric Research, one of the leading international pediatric journals, showing the benefits of the GASMAS-technology, used, and patented by Neola...
Neola Medical publishes prospectus in connection with the forthcoming rights issue

Neola Medical publishes prospectus in connection with the forthcoming rights issue

Sep 28, 2022

This is a translation of the Swedish press release published 2022-09-27 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE,...
Clinical study on 100 newborn babies with Neola Medical’s medical technology device completed, positive subgroup results presented

Clinical study on 100 newborn babies with Neola Medical’s medical technology device completed, positive subgroup results presented

Sep 21, 2022

This is a translation of the Swedish press release 2022-09-21 The recruitment of 100 newborn babies to the clinical study NIOMI (Non-Invasive Lung Oxygen Monitoring in Term Infants) at University College Cork, Ireland, have now been completed. Positive subgroup...
Acquisition of IP rights, clinical study results, owner’s increased shares and the coming rights issue – CEO tells more in Neola Medicals investor letter

Acquisition of IP rights, clinical study results, owner’s increased shares and the coming rights issue – CEO tells more in Neola Medicals investor letter

Sep 15, 2022

This is a translation of the Swedish press release 2022-09-15 In this falls investor letter (in Swedish) CEO Hanna Sjöström tells more about the upcoming rights issue that is guaranteed to 80 %, the acquisition of IP rights and the positive results from the first 50...
Neola Medical’s CEO Hanna Sjöström presents at ABG Sundal Colliers Investor Day the 13th of September

Neola Medical’s CEO Hanna Sjöström presents at ABG Sundal Colliers Investor Day the 13th of September

Sep 12, 2022

This is a translation of the Swedish press release published 2022-09-12 Neola Medical AB (publ) will participate at ABG Sundal Colliers Investor Day in Stockholm the 13th of September and present the company. At 15.00 (3 pm) CEO Hanna Sjöström will present the...
« Older Entries
Next Entries »
About Neola Medical

Neola Medical AB (publ) aims to advance neonatal intensive care with Neola®, a medical device designed to enable continuous lung monitoring and real-time alerts of potentially life-threatening complications. The technology is based on a cutting-edge spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola® has the potential to support better care, shorten time spent in intensive care, and contribute to healthier lives for preterm born babies. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical builds on Sweden’s legacy of medical technology innovation and contributions to global health care.

Sweden, HQ

Neola Medical AB
Ideon Gateway
Scheelevägen 27
223 63 Lund
info@neolamedical.com

U.S. Office

Neola Medical, Inc.
Nordic Innovation House
470 Ramona Street PMB
Palo Alto CA 94301-1707
info@neolamedical.com

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPersonal Data Policy